Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard acquired 41,259 shares of the firm’s stock in a transaction on Tuesday, September 20th. The shares were purchased at an average cost of $4.77 per share, for a total transaction of $196,805.43. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.94 on Friday. Argos Therapeutics Inc. has a one year low of $1.61 and a one year high of $13.97. The company’s market cap is $203.51 million. The company’s 50 day moving average is $4.80 and its 200 day moving average is $5.95.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, equities analysts predict that Argos Therapeutics Inc. will post ($1.55) earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new position in shares of Argos Therapeutics during the second quarter worth $137,000. Schwab Charles Investment Management Inc. purchased a new position in Argos Therapeutics during the second quarter worth approximately $137,000. KCG Holdings Inc. purchased a new position in Argos Therapeutics during the second quarter worth approximately $163,000. BlackRock Investment Management LLC raised its position in Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the period. Finally, Geode Capital Management LLC raised its position in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the period. Institutional investors own 11.05% of the company’s stock.

Several brokerages have weighed in on ARGS. Zacks Investment Research cut shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. FBR & Co reaffirmed a “buy” rating on shares of Argos Therapeutics in a research note on Tuesday, June 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Friday, June 17th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $11.00 price objective on shares of Argos Therapeutics in a research note on Monday, June 20th. Eight research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $11.50.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.